Company Focus
Teva Pharmaceutical Industries
Latest Teva Pharmaceutical Industries News
Generics
Israel’s Teva Pharmaceutical Industries today reported results for the quarter ended March 31, 2025. 7 May 2025
Related News
Insights
Company Spotlight
A Munich, Germany-based biotech company in the antibody drug conjugate (ADC) space.
Latest News & Features of interest to Teva Pharmaceutical Industries
Biotechnology
Precision oncology start-up Fore Biotherapeutics, founded in 2011, today announced a $38 million Series D-2 financing. 22 May 2025
Biotechnology
Chinese drugmaker Jiangsu Hengrui Pharmaceuticals priced its Hong Kong stock offering at the top of the marketed range to raise HK$9.9 billion ($1.3 billion). 22 May 2025
Biotechnology
US clinical-stage biotech Vigil Neuroscience saw its share price skyrocket more than 240% to $7.89 pre-market, on the news that French pharma major Sanofi had made a takeover bid for the company. 22 May 2025
Pharmaceutical
USA-based UroGen Pharma, a biotech developing and commercializing innovative solutions that treat urothelial and specialty cancers, closed 45% lower Wednesday. 22 May 2025
Pharmaceutical
UK pharma major AstraZeneca is set to present data from more than 80 studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Spanning across 20 approved and investigational medicines, the presentations include two plenary sessions and a special late-breaking abstract. 22 May 2025
Biotechnology
Privately-held US genome-scale drug discovery company Orionis Biosciences has announced a second multi-year collaboration with Genentech, a subsidiary of Roche , to discover small-molecule monovalent glue medicines for novel and challenging targets in oncology. 22 May 2025
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of Cancer Oncology (ASCO) meeting across its expansive cancer portfolio. 21 May 2025
Pharmaceutical
The Dementia Discovery Fund (DDF) - managed by healthcare fund manager SV Health Investors - has announced the final closing of its second fund, DDF-2, with $269 million in commitments. 21 May 2025
Pharmaceutical
Pharmasyntez, one of Russia’s leading drugmakers, plans a significant expansion of its portfolio of innovative drugs in the short-term, according to recent statements, made by representatives of the company, reports The Pharma Letter’s local correspondent. 21 May 2025
Biotechnology
US biotechs Protagenic Therapeutics and Phytanix Bio have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction. 21 May 2025
Latest In Brief for Teva Pharmaceutical Industries
Biotechnology
The Indian subsidiary of UK pharma major AstraZeneca has announced a Central Drugs Standard Control Organization (CDSCO) approval to import for sale and distribution of trastuzumab deruxtecan concentrate for solution for infusion 100mg for an additional indication, according to a Healthcare Radius report. 12 May 2025
Latest Relevant Ones To Watch News
US clinical-stage biotech Vigil Neuroscience saw its share price skyrocket more than 240% to $7.89 pre-market, on the news that French pharma major Sanofi had made a takeover bid for the company. 22 May 2025
28 April 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze